Practice Variability in the Management of Subrenal Arterial Stenoses in Seven Belgian Hospitals

Abstract

This multicentre retrospective study describes the variation of therapeutic options, treatment outcomes and costs for treating subrenal arterial stenoses as observed in daily practice in 1991-99 in seven Belgian hospitals. Data were obtained from clinical record review and from the sickness fund claims database, and included preoperative functional state, presence of acute ischaemia, diabetes and polyvascular disease, state of the lower-leg run-off arteries, anatomical site and type of lesion, type of treatment, result at 30 days and up to 4 years. A total of 441 episodes were studied, but most analyses dealt with a subgroup of 140 lesions in the common iliac up to the superficial femoral artery. The proportion of surgical treatments (as compared to an endovascular or mixed approach) varied from 15% to 81% between the hospitals.

In univariate patency analysis, relapse or failure rates at 4 years ranged from 5% for the common iliac artery to 35% for the superficial femoral artery. Polyvascular disease, a poor run-off, multiple stenoses and chronic occlusion were significant risk factors; age and diabetes were not. In the multivariate (stratified Cox regression) analysis, only a location in the superficial femoral artery and a poor preoperative clinical stage were significant risk factors, but type of therapeutic approach was not.

The total average cost of treatment was 5,300 荤, of which 15% was contributed by the patient. Surgery was associated with longer stays (median at 11 days) than endovascular treatments (median 1 days), and was 1.9 times more expensive. In conclusion, the results of the present study suggest that a multidisciplinary approach, orienting the patient to the most appropriate therapeutic pathway, could increase both the quality and the cost-effectiveness of the care.

Key Words:

• Clinical practice variation
• angioplasty
• vascular surgical procedures
• peripheral arterial occlusive disease
• treatment outcome
• cost analysis

Additional information

Notes on contributors

R. Mertens

Dr. Raf Mertens ANMC 579 Chée d’Haecht B-1031 Bruxelles, Belgium E-mail: [email protected]